MedTrace Logo

CPAP to Treat Cognitive Dysfunction in MS

NCT02544373 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2022-09-14

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to determine the effects of obstructive sleep apnea (OSA) on cognitive function in patients with multiple sclerosis (MS); and to evaluate whether OSA treatment with positive airway pressure therapy could improve cognitive dysfunction in MS patients who have OSA.

Conditions

Interventions

DEVICE

PAP therapy

Positive airway pressure treatment for obstructive sleep apnea

Sponsors & Collaborators

Principal Investigators

  • Tiffany Braley, MD, MS · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-12
Primary Completion
2021-06-25
Completion
2021-06-25
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544373 on ClinicalTrials.gov